Amosartan plus L
Alternative Names: HCP-1803Latest Information Update: 09 Jan 2025
Price :
$50 *
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Essential hypertension
Most Recent Events
- 23 Dec 2024 Hanmi Pharmaceutical plans to launch amosartan plus L tablet in 2025
- 21 Jun 2024 Efficacy and adverse events data from phase-III HM_APOLLO trial in Essential hypertension released by Hanmi Pharmaceutical
- 25 Mar 2024 Hanmi Pharmaceutical Company initiates a phase III trial for Essential hypertension in South Korea (PO) (NCT06438172)